• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Escape from mineralocorticoid excess: the role of angiotensin II.

作者信息

Biollaz J, Dürr J, Brunner H R, Porchet M, Gavras H

出版信息

J Clin Endocrinol Metab. 1982 Jun;54(6):1187-93. doi: 10.1210/jcem-54-6-1187.

DOI:10.1210/jcem-54-6-1187
PMID:6281293
Abstract

Escape from the sodium-retaining action of mineralocorticoids coincides with the suppression of plasma renin and angiotensin II levels. The purpose of this study was to evaluate whether blockade of the renin system accelerates this escape. Eight male normotensive volunteers, aged 24--33 yr, were maintained during two subsequent periods of 12 days each, separated by 3--4 weeks, on a constant intake of sodium and potassium of 140 mmol/day. During both periods, fludrocortisone acetate (0.2 mg) was administered orally three times a day on days 4--12. In addition, on days 3--12, either a converting enzyme inhibitor (MK 421;20 mg orally, twice daily) or a placebo was added in double blind fashion and randomized sequence. During both periods, blood pressures were similar; they tended to increase slightly toward day 12. The weight increase did not differ between the two periods. With MK 421, angiotension II levels were significantly lower than with placebo on days 3--6 (P less than 0.001). On the same days, PRA was increased due to converting enzyme blockade. Despite the significantly different angiotensin II levels on days 3--6, daily urinary sodium excretion on all individual days as well as cumulative sodium balance were the same during both periods. Therefore, we could find no evidence in man that suppression of circulating angiotensin II levels is causally related to escape from mineralocorticoid excess.

摘要

相似文献

1
Escape from mineralocorticoid excess: the role of angiotensin II.
J Clin Endocrinol Metab. 1982 Jun;54(6):1187-93. doi: 10.1210/jcem-54-6-1187.
2
Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.卡托普利和依那普利对缺钠犬钠排泄及血压的影响。
Fed Proc. 1984 Apr;43(5):1336-41.
3
Potassium supplementation ameliorates mineralocorticoid-induced sodium retention.补钾可改善盐皮质激素引起的钠潴留。
Kidney Int. 1993 May;43(5):1097-103. doi: 10.1038/ki.1993.154.
4
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.用MK 421进行抗高血压治疗:血管紧张素II - 肾素关系以评估转换酶阻断的疗效。
J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):966-72.
5
Glucocorticoid and mineralocorticoid stimulation of atrial natriuretic peptide release in man.糖皮质激素和盐皮质激素对人体心房利钠肽释放的刺激作用。
J Clin Endocrinol Metab. 1988 Jun;66(6):1233-9. doi: 10.1210/jcem-66-6-1233.
6
The influence of sodium intake on physiological responses to angiotensin II in conscious dogs.钠摄入量对清醒犬体内血管紧张素II生理反应的影响。
Scand J Urol Nephrol Suppl. 1984;79:29-34.
7
Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects.
J Cardiovasc Pharmacol. 1984 May-Jun;6(3):436-41. doi: 10.1097/00005344-198405000-00010.
8
Human atrial natriuretic polypeptide during escape from mineralocorticoid excess in man.人体从醛固酮增多状态恢复过程中的人心房利钠多肽。
Clin Sci (Lond). 1987 Oct;73(4):431-6. doi: 10.1042/cs0730431.
9
Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects.不含巯基的血管紧张素转换酶抑制剂(MK421):肾素系统在血压正常受试者中的作用证据
Br Med J (Clin Res Ed). 1981 Aug 8;283(6288):401-3. doi: 10.1136/bmj.283.6288.401.
10
Effect of administered mineralocorticoids or ACTH in pregnant women. Attenuation of kaliuretic influence of mineralocorticoids during pregnancy.给予盐皮质激素或促肾上腺皮质激素对孕妇的影响。孕期盐皮质激素排钾作用的减弱。
J Clin Invest. 1972 Jun;51(6):1301-9. doi: 10.1172/JCI106926.

引用本文的文献

1
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.高血压管理中的新治疗选择:评估阿齐沙坦美索米酯的潜在作用。
Integr Blood Press Control. 2012;5:19-25. doi: 10.2147/IBPC.S13784. Epub 2012 Mar 12.
2
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection.实验性轻度肾功能不全介导早期心脏细胞凋亡、纤维化和舒张功能障碍:肾脏-心脏关联。
Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15;302(2):R292-9. doi: 10.1152/ajpregu.00194.2011. Epub 2011 Nov 9.
3
End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.
高血压患者的靶器官保护:聚焦血管紧张素受体阻滞剂对肾功能的作用。
Drugs. 2011 May 28;71(8):1003-17. doi: 10.2165/11591350-000000000-00000.
4
Angiotensin II-receptor antagonist in the treatment of hypertension.血管紧张素II受体拮抗剂在高血压治疗中的应用
Curr Hypertens Rep. 2005 Aug;7(4):287-93. doi: 10.1007/s11906-005-0027-y.
5
Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway.
J Clin Invest. 1994 Nov;94(5):1938-46. doi: 10.1172/JCI117544.